# Eric YU

> Eric YU is a Series A investor at Matrix Partners China backing Biotechnology and Pharmaceutical. See 8 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [Matrix Partners China](https://shizune.co/investors/profile/matrix-partners-china)
- Total investments: 8
- Last investment: Jun 2023
- Lead investor: 38%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/eric-yu-870a30

Eric YU is a Series A investor at Matrix Partners China focused on Biotechnology and Pharmaceutical. Eric YU is based out of Huangpu District, Shanghai and is the Partner, Head of Healthcare of Matrix Partners China. Eric previously worked at Fidelity Growth Partners Asia as a VP. Eric YU attended the The Tuck School of Business at Dartmouth.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 3 | 38% |
| Pharmaceutical | 3 | 38% |
| Health Care | 2 | 25% |
| Manufacturing | 2 | 25% |
| Medical Device | 2 | 25% |

12 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 3 | 38% |
| Series B | 3 | 38% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Ucello Therapeutics | Ucello Therapeutics is engaged in development of allogeneic cell therapies using its proprietary CAR-T cell technology platform CBT-X20. | $21.2M | Series A | Jun 02, 2023 |  |
| Ucello Therapeutics | Ucello Therapeutics is engaged in development of allogeneic cell therapies using its proprietary CAR-T cell technology platform CBT-X20. | $25M | Series A | Feb 10, 2022 |  |
| Triastek | Triastek develops 3D printed medicines and the production facilities to manufacture them and has already filed patent applications for its technology. |  | Series B | Nov 23, 2021 |  |
| Scivita Medical Technology | Scivita Medical is a high-tech enterprise engaged in the field of optical diagnosis and treatment, multidimensional images development, high-performance materials research and precision manufacturing with minimally invasive medical treatment. Scivita Medical's product covers both flexible endoscopy and rigid endoscopy, and has uniqueadvantages in the research and commercialization of all cutting-edge technologies in the field of medical endoscopes. It has ultra-high-definition visualization technology (such as 4K UHD visualization), 3D visualization technology, special light visualization technology (such as fluorescence visualization), ultra-fine endoscopic visualization technology, single-use technology, etc. | $61.9M | Series B | Aug 05, 2021 |  |
| Triastek | Triastek develops 3D printed medicines and the production facilities to manufacture them and has already filed patent applications for its technology. | $51M | Series B | Jun 24, 2021 |  |
| Scivita Medical Technology | Scivita Medical is a high-tech enterprise engaged in the field of optical diagnosis and treatment, multidimensional images development, high-performance materials research and precision manufacturing with minimally invasive medical treatment. Scivita Medical's product covers both flexible endoscopy and rigid endoscopy, and has uniqueadvantages in the research and commercialization of all cutting-edge technologies in the field of medical endoscopes. It has ultra-high-definition visualization technology (such as 4K UHD visualization), 3D visualization technology, special light visualization technology (such as fluorescence visualization), ultra-fine endoscopic visualization technology, single-use technology, etc. | $61.7M | Series A | Apr 26, 2021 |  |
| OnQuality Pharmaceuticals | OnQuality Pharmaceuticals offers trials to assess the safety and efficacy of a targeted supportive care agent that addresses the specific side effects of vascular endothelial growth factor receptor (VEGFR) inhibitors among cancer patients. | $20M | Series A | Mar 31, 2021 |  |
| 23Mofang | 23Mofang provides genetic testing services for Chinese people and conducts life data analysis business. The company relies on the Internet + genetic testing to build a large database of life, with the mission of "data life, benefit everyone", and build a trustworthy technology enterprise. | $14.2M | Series B | Mar 05, 2018 |  |

8 of 8 investments shown.

## Co-investors
- [Cowin Venture](https://shizune.co/investors/profile/cowin-venture) — VC Fund, 2 deals together
- [GL Ventures](https://shizune.co/investors/profile/gl-ventures) — VC Fund, 2 deals together
- [GL Ventures LLC](https://shizune.co/investors/profile/gl-ventures-llc) — VC Fund, 2 deals together
- [Inno-Chip](https://shizune.co/investors/profile/inno-chip) — VC Fund, 2 deals together
- [Lilly Asia Ventures](https://shizune.co/investors/profile/lilly-asia-ventures) — VC Fund, 2 deals together
- [TriWise Capital](https://shizune.co/investors/profile/triwise-capital) — VC Fund, 2 deals together

## About Matrix Partners China

VC Fund · Beijing, China

Matrix Partners China builds long-term relationships with entrepreneurs and helps them build significant, industry-leading companies.Since its inception in 1977, Matrix Partners China has made hundreds of investments and played an active role in the development of many successful businesses, 50 of which went on to IPO, and 75 of which have goneon to profitable M&A events. The firm consistently ranks in the top venture firms in terms of returns to its investors.Matrix Partners China combines local knowledge with global experience and vision. Its team consists of both former entrepreneurs and experienced investors. Its past successes include Focus Media, Eachnet, and Baidu, among others. The company invests across multiple sectors and stages.

5 contacts available at Matrix Partners China.

| Name | Title | Profile |
| --- | --- | --- |
| Eric YU | Partner, Head of Healthcare | https://shizune.co/investors/profile/eric-yu-2 |
| Guoxiong Cao | Partner (RMB Funds) | https://shizune.co/investors/profile/guoxiong-cao |
| Kevin Xiong | Partner | https://shizune.co/investors/profile/kevin-xiong |
| Mi Zhou | Director | https://shizune.co/investors/profile/mi-zhou |
| Bo Shao | Founding Managing Partner | https://shizune.co/investors/profile/bo-shao |

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does Eric YU invest in?

Eric YU invests primarily in Biotechnology, Pharmaceutical and Health Care startups, most often at Series A and Series B stage. Most of the 8 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Eric YU last invest?

The most recent investment recorded for Eric YU closed in Jun 2023. Shizune tracks 8 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co